Investment Thesis
Oncolytics Biotech faces severe financial distress with negative stockholders' equity of -5.1M, no revenue generation, and operating losses of 9.3M per quarter. The company is burning 7.3M annually in operating cash flow against only 5.5M in cash reserves, creating a sub-one-year runway before requiring external capital or facing insolvency.
Strengths
- Maintains 5.5M in cash equivalents providing near-term liquidity cushion
- Minimal capital expenditure (6K) suggests lean operations and cash preservation focus
- Current ratio of 1.38x provides some buffer above immediate solvency threshold
Risks
- Negative stockholders' equity of -5.1M indicates technical insolvency and balance sheet insolvency
- No revenue generation with no disclosed commercialization timeline for products
- Operating cash burn of 7.3M annually exhausts remaining cash within 9-12 months without capital raise
- Net loss deteriorating 26.2% year-over-year indicating worsening operational performance
- Future capital raises will cause substantial shareholder dilution given negative equity position
- ROA of -113.3% shows severe asset inefficiency and value destruction
Key Metrics to Watch
- Cash balance depletion rate and timeline to next capital raise
- Clinical trial progress and regulatory milestone achievements
- Operating cash burn trend and path to breakeven
- Stockholders equity trend and recovery to positive territory
- Revenue recognition and commercialization announcements
Financial Metrics
Revenue
N/A
Net Income
-9.2M
EPS (Diluted)
$-0.08
Free Cash Flow
-7.3M
Total Assets
8.2M
Cash
5.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
N/A
ROA
-113.3%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
1.38x
Quick Ratio
1.38x
Debt/Equity
N/A
Debt/Assets
162.9%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T09:56:08.786307 |
Data as of: 2026-03-31 |
Powered by Claude AI